Nexstim Plc · OMXHEX:NXTMH
Nexstim — ProHearings, Stockholm 2020
21 slides from Nexstim's conference presentation, Nov 27, 2020
Slide 1: Nexstim. Personalised depression treatment.
Nexstim. Personalised depression treatment. Mikko Karvinen| CEO | Nexstim Plc Nexstim Plc Corporate Presentation, ProHearings, Stockholm 27 November 2020
Slide 2: Important Information
Important Information This document and the information contained herein are being presented by Nexstim Oyj (“Nexstim” or the “Company”). In connection with any presentation or review of Certain of the information contained herein concerning industry and market data, this document, you agree to be b
Slide 3: Table of Contents
Table of Contents • Overview • Therapeutic ‒ Major Depressive Disorder (MDD) ‒ Chronic Neuropathic Pain • Diagnostic ‒ Pre-surgical Mapping • Business Update & Key Financials Confidential Presentation 3
Slide 4: Unique proprietary neuronavigated TMS technology
Nexstim has a unique proprietary neuronavigated TMS technology that delivers best in class mapping and treatment for patients with brain diseases and disorders. We are well positioned to a disruptive shift in depression treatment and therapy delivery. With improving economics, driven by record reven
Slide 5: Personalised Transcranial Magnetic Stimulation (TMS)
Personalised Transcranial Magnetic Overview Stimulation (TMS) SmartFocus® Technology with a Highly Sophisticated 3D Navigation Unique & Proprietary • Commercial-stage med tech company with a unique, proprietary Technology navigated neuro-stimulation technology for diagnostic and therapeutic applicat
Slide 6: Proprietary Navigated TMS System
Overview Proprietary Navigated TMS System Only TMS technology with ability to take the uniqueness of a patient’s brain into consideration for therapeutic and diagnostic applications Commercial Use System Application Europe US Status FDA approved with Multiple systems Depression CE marked existing in
Slide 7: Nexstim SmartFocus TMS in Depression
Nexstim SmartFocus® TMS in Depression Entering a rapidly growing market with a differentiated product
Slide 8: NBT for Depression
NBT® for Depression Therapeutic Nexstim depression business opportunity Market size estimate2 (patients) People affected by MDD globally • Major depressive disorder affects 2-5% of the 216m population in developed countries1 Patients not responding to medicines and seeking treatment • Existing psych
Slide 9: Promising Clinical Outcomes
Therapeutic Promising Clinical Outcomes Patients completing SmartFocus® rTMS Treatment of MDD • First 108 patients in Nexstim’s patient registry have completed SmartFocus® rTMS therapy for treatment of MDD at clinical sites in the US • 42% of the patients completing the treatment achieved clinical r
Slide 10: Nexstim SmartFocus TMS in Chronic Neuropathic Pain
Nexstim SmartFocus® TMS in Chronic Neuropathic Pain
Slide 11: NBT for Chronic Neuropathic Pain
NBT® for Chronic Neuropathic Pain Therapeutic Nexstim neuropathic pain business opportunity Market size of estimate2 • There are about 10 million addressable neuropathic pain People affected by 285 chronic neuropathic pain patients in the US and Europe1 m annually • 40-50% of neuropathic pain patien
Slide 12: Nexstim SmartFocus TMS in Diagnostics
Nexstim SmartFocus® TMS in Diagnostics Proprietary technology enabling substantial increase in progression-free survival in brain cancer surgery, commercially validated
Slide 13: NBS for Pre-surgical Mapping (Diagnostic)
NBS for Pre-surgical Mapping Diagnostic (Diagnostic) Only available technology on the market today NBS Significantly Improves Clinical Outcomes in World-leading Centers Rely on Nexstim‘s Pre-surgical Neurosurgery Mapping Technology NBS Selected institutions out of the 170 ones NBS helps surgeons to
Slide 14: Nexstim Business Update & Key Financials
Nexstim Business Update & Key Financials
Slide 15: Nexstim Business Update H1 2020
Nexstim Business Update H1 2020 Business Operations • Focused on minimizing the effect of COVID-19 pandemic as well as updating Company strategy • Strong progress considering the difficult business environment ‒ Four new NBS systems sold (three in the US and one in Europe) ‒ Total of five new NBT® s
Slide 16: Key Performance Indicators H1 2020
Business Operations Key Performance Indicators H1 2020 1-6/2020 1-6/2019 1-12/2019 (EUR in thousands) 6 months 6 months 12 months • All time high H1 Net Sales Net sales 1,614.5 1,217.4 3,348.1 • Total Net Sales increased by +33% Personnel expenses -1,597.3 -2,079.1 -4,713.0 • NBS sales EUR 0.9M (+47
Slide 17: NBT / NBS Revenue – Existing Business
NBT® / NBS Revenue – Existing Business Operations Business Cumulative YTD Total Revenue 2018-2020 4 000 000 € • Steadily growing business, showing all time high 3 500 000 € figures in H1 2020 3 000 000 € 2 500 000 € • Rolling 12 months revenue has been staying well 2 000 000 € above the growing tren
Slide 18: Additional Revenue Opportunities
Business Operations Additional Revenue Opportunities Accelerated iTBS protocol revenue US Nexstim clinics revenue • Entry to the large untapped hospital inpatient TMS • Partnership business model opportunity with path to market in severe depression as well as post-remission near-term profitability o
Slide 19: Near-term Objectives / Milestones
Near-term Objectives / Milestones Business Operations Decrease the operating loss with focus on achieving profitable revenue growth and strict management of 1 operating expenses. Full year 2020 net sales are estimated to increase, and operating loss is expected to decrease in comparison to year 2019
Slide 20: Unique proprietary neuronavigated TMS technology
Nexstim has a unique proprietary neuronavigated TMS technology that delivers best in class mapping and treatment for patients with brain diseases and disorders. We are well positioned to a disruptive shift in depression treatment and therapy delivery. With improving economics, driven by record reven
Slide 21: Thank you!
Thank you! Public Presentation 21